Levente Kollár

Mr. Levente Kollár

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2021 in Cells
Verified
Journal Article
Open access
PDF file
LKLevente Kollár
Levente Kollár
MGMartina Gobec
Martina Gobec
MPMatic Proj
Matic Proj
LSLara Smrdel
Lara Smrdel
Damijan KnezDamijan Knez
Damijan Knez
György M KeserűGyörgy M Keserű
György M Keserű
Constitutive- and immunoproteasomes are part of the ubiquitin–proteasome system (UPS), which is responsible for the protein homeostasis. Selective inhibition of the immunoproteasome offers opportunities for the treatment of numerous diseases, including inflammation, autoimmune diseases, and hematologic malignancies. Although several inhibitors have been reported, selective nonpeptidic inhibitors are sparse. Here, we describe two series of compounds that target both proteasomes. First, benzoxazole-2-carbonitriles as fragment-sized covalent immunoproteasome inhibitors are reported. Systematic substituent scans around the fragment core of benzoxazole-2-carbonitrile led to compounds with single digit micromolar inhibition of the β5i subunit. Experimental and computational reactivity studies revealed that the substituents do not affect the covalent reactivity of the carbonitrile warhead, but mainly influence the non-covalent recognition. Considering the small size of the inhibitors, this finding emphasizes the importance of the non-covalent recognition step in the covalent mechanism of action. As a follow-up series, bidentate inhibitors are disclosed, in which electrophilic heterocyclic fragments, i.e., 2-vinylthiazole, benzoxazole-2-carbonitrile, and benzimidazole-2-carbonitrile were linked to threonine-targeting (R)-boroleucine moieties. These compounds were designed to bind both the Thr1 and β5i-subunit-specific residue Cys48. However, inhibitory activities against (immuno)proteasome subunits showed that bidentate compounds inhibit the β5, β5i, β1, and β1i subunits with submicromolar to low-micromolar IC50 values. Inhibitory assays against unrelated enzymes showed that compounds from both series are selective for proteasomes. The presented nonpeptidic and covalent derivatives are suitable hit compounds for the development of either β5i-selective immunoproteasome inhibitors or compounds targeting multiple subunits of both proteasomes.

18 December 2023 in Organic Letters
Verified
Journal Article
Open access
ANAndrás Gy. Németh
András Gy. Németh
LKLevente Kollár
Levente Kollár
KNKrisztina Németh
Krisztina Németh
GSGitta Schlosser
Gitta Schlosser
AMAnnamária Minus
Annamária Minus
György M KeserűGyörgy M Keserű
György M Keserű
The increasing role of the DNA-encoded library technology in early phase drug discovery represents a significant demand for DNA-compatible synthetic methods for therapeutically relevant heterocycles. Herein, we report the first on-DNA synthesis of multisubstituted indoles via a cascade reaction of Sonogashira coupling and intramolecular ring closure. Further functionalization by Suzuki coupling at the third position exploits a diverse chemical space. The high fidelity of the method also enabled the construction of an indole-based mock library.

14 November 2023 in Chemphyschem
Verified
Journal Article
Open access
LMLevente M. Mihalovits
Levente M. Mihalovits
LKLevente Kollár
Levente Kollár
DBDávid Bajusz
Dávid Bajusz
Damijan KnezDamijan Knez
Damijan Knez
KBKrištof Bozovičar
Krištof Bozovičar
György M KeserűGyörgy M Keserű
György M Keserű
Heterocyclic thiones have recently been identified as reversible covalent warheads, consistent with their mild electrophilic nature. Little is known so far about their mechanism of action in labelling nucleophilic sidechains, especially cysteines. The vast number of tractable cysteines promotes a wide range of target proteins to examine; however, our focus was put on functional cysteines. We chose the main protease of SARS‐CoV‐2 harboring Cys145 at the active site that is a structurally characterized and clinically validated target of covalent inhibitors. We screened an in‐house, cysteine‐targeting covalent inhibitor library which resulted in several covalent fragment hits with benzoxazole, benzothiazole and benzimidazole cores. Thione derivatives and Michael acceptors were selected for further investigations with the objective of exploring the mechanism of inhibition of the thiones and using the thoroughly characterized Michael acceptors for benchmarking our studies. Classical and hybrid quantum mechanical/molecular mechanical (QM/MM) molecular dynamics simulations were carried out that revealed a new mechanism of covalent cysteine labelling by thione derivatives, which was supported by QM and free energy calculations and by a wide range of experimental results. Our study shows that the molecular recognition step plays a crucial role in the overall binding of both sets of molecules.

22 May 2026 in ChemMedChem
Verified
Journal Article
Open access
LKLevente Kollár
Levente Kollár
LMLevente M. Mihalovits
Levente M. Mihalovits
DBDávid Bajusz
Dávid Bajusz
Damijan KnezDamijan Knez
Damijan Knez
JSJózsef Simon
József Simon
György M KeserűGyörgy M Keserű
György M Keserű
Linking of fragments in neighboring binding sites is one of the optimization strategies in fragment‐based drug discovery, where additive or even more substantial bioactivity improvements can be realized. However, such efforts present a considerable challenge when one fragment binds covalently to the target protein, as small modifications can influence the correct positioning of the covalent warhead toward the targeted nucleophilic residue. Here, we present a case study of fragment linking that yielded single‐digit micromolar, covalent inhibitors of the SARS‐CoV‐2 main protease, starting from fragments that were inactive in the biochemical assay. Using structural information from a recent, high‐throughput crystallographic fragment screen, we show that the success of fragment linking in the design of targeted covalent inhibitors is heavily impacted by several factors, including the warhead type, the labeling chemistry, and even subtle changes in the designed linker. Notably, we observe that induced fit effects might override the original fragment orientations in the linked molecule, highlighting the need for reliable structure verification, especially in consecutive rounds of fragment elaboration.

18 September 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
VLVincenzo Di Lorenzo
Vincenzo Di Lorenzo
NCNoémI Csorba
NoémI Csorba
RSRenátA Szabó
RenátA Szabó
LKLevente Kollár
Levente Kollár
YRYvette Roske
Yvette Roske
György M KeserűGyörgy M Keserű
György M Keserű
Covalent mechanism of action is a powerful way to modulate challenging drug targets. Here, we present a streamlined workflow that combines covalent fragment screening (electrophile first approach) and ligand-first strategy to identify covalent inhibitors targeting lysine residues in the allosteric latch site of SHP2 phosphatase. Supported by complementary computational and experimental analyses, this strategy enabled us to identify the first potent cell active allosteric covalent inhibitors acting at this site. Demonstrating the covalent tractability of the latch site opens further avenues for future optimization and therapeutic exploration of high-value allosteric SHP2 inhibitors.